We serve Chemical Name:5-Chloroisophthalaldehyde CAS:105511-08-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Chloroisophthalaldehyde
CAS.NO:105511-08-8
Synonyms:5-chlorobenzene-1,3-dicarbaldehyde
Molecular Formula:C8H5ClO2
Molecular Weight:168.57700
HS Code:2913000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:34.14000
Exact Mass:167.99800
LogP:1.96500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-chlorobenzene-1,3-dicarbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-chlorobenzene-1,3-dicarbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-chlorobenzene-1,3-dicarbaldehyde Use and application,5-chlorobenzene-1,3-dicarbaldehyde technical grade,usp/ep/jp grade.
Related News: Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 5-Chloroisophthalaldehyde manufacturer On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday. 5-Chloroisophthalaldehyde supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 5-Chloroisophthalaldehyde vendor Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 5-Chloroisophthalaldehyde factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.
